8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
Edwards Lifesciences Corp (EW)

Edwards filed an 8‑K (Item 9.01) on Feb 10, 2026: Exhibit 99.1 is a press release reporting Q4 2025…

Filed with the SEC on · Summarized by InvestorsBot

Edwards filed an 8‑K (Item 9.01) on Feb 10, 2026: Exhibit 99.1 is a press release reporting Q4 2025 financial results; Exhibit 104 is the Inline XBRL cover page. See press release for the actual numbers. $EW 📄 #Earnings #MedTech

Press release dated Feb 10, 2026 contains Edwards’ Q4 2025 results — investors should review for revenue, EPS, guidance and any material updates. Filing points to exhibits for details. $EW 🔎 #InvestorAlert #Healthcare

8‑K was signed by CFO Scott B. Ullem on Feb 10, 2026. This is an administrative earnings disclosure with exhibits (99.1 and 104) attached. $EW ✅ #Compliance #Earnings

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from Edwards Lifesciences Corp

Edwards Lifesciences Raises 2026 Guidance After 13.6% Q2 Sales Growth

8-K · July 23, 2026

Edwards Lifesciences ($EW) issued a press release on Feb 10, 2026 reporting Q4 2025 financial results; the…

8-K · February 10, 2026

Edwards Lifesciences filed an 8‑K (Item 9.01) on Jan 12, 2026 — Exhibit 99.1: Press Release dated Jan 9,…

8-K · January 12, 2026

Jan 9, 2026 — U.S.

8-K · January 12, 2026